Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30005990 | 1.00 | ERN1 (0.36) | ERN1CYP2C9CYP3A4CYP2C19HDAC1 | |
| SCHEMBL14448986 | 0.83 | ERN1 (0.36) | ERN1CYP2C9CYP3A4CYP2C19HDAC1 | |
| SCHEMBL2009048 | 0.82 | CYP2C9 (0.36) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL30826192 | 0.78 | ERN1 (0.36) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL29628640 | 0.78 | ERN1 (0.38) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL12384956 | 0.78 | ERN1 (0.38) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL1197434 | 0.78 | CYP2C9 (0.45) | ERN1CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL21196123 | 0.77 | ERN1 (0.34) | ERN1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL20872683 | 0.76 | GABRA1 (0.43) | CYP2C9CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL20607903 | 0.75 | ERN1 (0.45) | ERN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4587437-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025106014-A1 | COMPOUNDS AND METHODS FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2025-05-22 | — | — | WO | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119192137-A | Inhibition of human integrin alpha4β7 | 莫菲克医疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240327425-A1 | KRAS G12D INHIBITOR AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024199524-A1 | COMPOUND AS PKMYT1 INHIBITOR | 江苏星盛新辉医药有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8143307-B2 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-03-27 | — | — | US | disclosed |
| CN-101137641-B | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RES INST CHEM TECH | 2010-11-24 | — | — | CN | disclosed |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-01-07 | — | — | US | disclosed |
| EP-1831192-A4 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RES INST CHEM TECH (KR) | 2009-08-19 | — | — | EP | disclosed |
| CN-101137641-A | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | KOREA RES INST CHEM TECH (KR) | 2008-03-05 | — | — | CN | disclosed |
| EP-1831192-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Korea Research Institute of Chemical Technology (KR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006071047-A1 | BENZOTHIOPHEN-2-CARBONYLGUANIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-06 | — | — | WO | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327425-A1 | KRAS G12D INHIBITOR AND USE THEREOF | KRAS, NRAS, HRAS | ERN1 912/4885CYP2C9 2725/4885CYP3A4 3815/4885 |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | ERN1 137/4885CYP2C9 3099/4885CYP3A4 2500/4885 |
| US-20100004466-A1 | Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same | TNNI3, TNNT2, SLC9A2 | ERN1 2133/4885CYP2C9 1091/4885CYP3A4 2616/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | ERN1 2368/4885CYP2C9 45/4885CYP3A4 27/4885 |
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | ERN1 361/4885CYP2C9 1278/4885CYP3A4 1636/4885 |
| US-20240425490-A1 | SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM2B, RRM2, RRM1 | ERN1 652/4885CYP2C9 3079/4885CYP3A4 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.